Bioheart, Inc. , a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of degenerative diseases, released today 6 month data from its phase I ANGEL Trial.
http://ift.tt/1f2qcxX
http://ift.tt/1f2qcxX
No comments:
Post a Comment